Review this exciting guide to some of the recent content additions to Practical Guidance, designed to help you find the tools and insights you need to work more efficiently and effectively. Practical Guidance...
By: Michael J. Lehet OGLETREE, DEAKINS, NASH, SMOAK & STEWART, P.C. THIS ARTICLE DISCUSSES HOW LAW FIRM attorneys can get the most out of their knowledge management (KM) department, and it covers...
By: Hilary Gerzhoy , Julienne Pasichow and Grace Wynn HWG LLP THIS ARTICLE DISCUSSES ETHICAL ISSUES LITIGATORS must be aware of when considering using generative artificial intelligence (AI) technology...
By: Ronald J. Levine HERRICK , FEINSTEIN LLP THIS ARTICLE DISCUSSES HOW TO MAKE pitches for new litigation business and covers topics such as preparing the presentation, effective communication techniques...
By: Ronald J. Levine HERRICK, FEINSTEIN LLP THIS ARTICLE PROVIDES GUIDANCE FOR LITIGATORS on developing new business and covers topics such as building your presence as a thought leader, marketing, and...
Copyright © 2024 LexisNexis and/or its Licensors.
By: Matthew D. Jenkins, Hunton Andrews Kurth LLP
This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response to the COVID-19 pandemic: (1) Medicare’s Advance Payment Program, (2) the Provider Relief Fund, and (3) the Paycheck Protection Program.
When you advise a healthcare company that receives federal funds about its compliance obligations, a basic understanding of the FCA is essential.
The FCA imposes civil penalties on persons who knowingly or with reckless disregard: CLICK HERE TO READ THE FULL ARTICLE IF YOU ARE A PRACTICAL GUIDANCE SUBSCRIBER